US Market News
2月前
MedTech's Edge: How AI and Remote Diagnostics Drive Scalable ValueMarch 27, 2026 10:15 AM
PR Newswire (US)
Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now actively deploying artificial intelligence, with well over half reporting a clear, measurable return on investment from AI-powered diagnostic imaging[2]. This pivotal convergence of decentralized care and automated clinical workflows is creating significant, scalable value for companies building remote diagnostics, implantable sensors, and robotic systems, including innovators like VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Senseonics (NASDAQ: SENS), Microbot Medical (NASDAQ: MBOT), LivaNova (NASDAQ: LIVN), Clover Health Investments (NASDAQ: CLOV).
Analysts tracking this massive outpatient migration are paying close attention to the data. Major health systems have already committed billions in new ambulatory surgery capacity since the start of the year. This movement is backed by federal policy, with Medicare adding over 500 procedures to its covered list for ambulatory surgery centers in the 2026 cycle[3]. Furthermore, industry analysis confirms that surgical robotics platforms are being completely re-engineered to operate in these streamlined, outpatient environments. This validates that expanding directly to the point of care is the primary value driver for next-generation medical technology positioning[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is expanding into remote healthcare after announcing a partnership with First Light Health, an Indigenous-owned medical services company based in Vancouver, to deliver AI-powered cardiac diagnostics to Indigenous and remote communities across Canada.Together, the two companies are developing a hub-and-spoke care model built around VentriPoint's VMS+™ system. Local providers in remote areas will capture ultrasound scans on-site and be supported by specialists at a central hub who are able to digitally access images and assist with interpretation. That gives patients in British Columbia, Yukon, Alberta, Manitoba, and New Brunswick access to advanced cardiac imaging without travelling hundreds of kilometres, at lower cost and with faster turnaround than traditional referral pathways. Following validation of the model, Ventripoint plans to scale it beyond Canada into underserved communities globally.VentriPoint's VMS+™ system converts standard 2D echocardiograms into detailed 3D volumetric images. The company says its accuracy is comparable to cardiac MRI, but at a fraction of the cost and without the infrastructure those machines require. For communities where heart disease rates are high and specialist access is limited, the difference between early diagnosis and late diagnosis can be the difference between treatment and tragedy."Cardiovascular disease doesn't respect geography, but too often, access to cardiac care does," said Hugh MacNaught, CEO of VentriPoint Diagnostics. "Our work with First Light Health and other First Nations partners such as the Nisga_'a Valley Health Authority demonstrates the need for a made-in-Canada innovation that can close that gap. We see the potential for this solution to be widely deployed, from the Arctic to the Amazon. This is what scalable, equitable heart care looks like."First Light Health brings cultural safety expertise and established relationships within First Nations communities, which matters when deploying health technology in populations that have historically been underserved by the broader system.The partnership builds on recent commercial traction. VentriPoint signed a commercial agreement with LG Consulting Solutions to support VMS+™ deployment across Northern California, targeting cardiac centres in the Sacramento and San Francisco regions. Before that, the company had already partnered with the Nisga_'a Valley Health Authority to pilot a similar model in northern BC.VentriPoint is a Toronto-based medtech company with regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform works with ultrasound equipment from any vendor and is built on over a decade of Knowledge Based Reconstruction technology development. The goal is simple: put MRI-grade cardiac diagnostics within reach of any clinic or community that needs them.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/In other industry developments and happenings in the market include:Senseonics (NASDAQ: SENS) presented first-ever real-world evidence for Eversense 365 at the 19th International Conference on Advanced Technologies & Treatments for Diabetes in Barcelona, with data from 5,059 real-world sensors demonstrating a mean transmitter wear time of 93.8%, a mean Glucose Management Indicator of 7.14%, and a mean Time in Range of 66% sustained consistently across both the first and second six-month periods of the one-year wear cycle. Over 75% of users achieved hypoglycemic targets, with patients aged 65 and older recording particularly strong outcomes including a mean GMI of 6.99%, mean TIR exceeding 70%, and wear time above 95%."The promise of a year-long CGM has now been demonstrated in the real world," said Francine Kaufman, M.D., Chief Medical Officer at Senseonics. "Since Eversense 365 was launched in the US, we have consistently heard positive feedback about the system and its impact from both patients and their healthcare providers. Today, we have presented real-world evidence that further validates our belief in this technology and what we are hearing from the diabetes community. The data demonstrate that Eversense 365 can perform exceptionally well and consistently across its entire lifespan, with strong adherence supporting a full year of positive glycemic outcomes with just one sensor."Early data from the first approximately 120 patients using the twiist Automated Insulin Delivery system combined with Eversense 365 showed a mean GMI of 6.79%, mean TIR of 77%, and time in hypoglycemia of 2.7%, all meeting international consensus targets. Senseonics also recently received European CE Mark approval for Eversense 365 and expects to launch in Germany, Italy, Spain, and Sweden in the coming months.Microbot Medical (NASDAQ: MBOT) achieved a landmark clinical milestone as Emory Healthcare completed the world's first robotic Prostatic Artery Embolization for benign prostatic hyperplasia and the first robotic Y-90 radioembolization mapping for liver cancer using its LIBERTY Endovascular Robotic System. The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures, targeting an estimated 40 million BPH patients in the U.S. alone."With a sizeable patient population, we believe that LIBERTY can establish endovascular robotic navigation as the standard of care for PAE in patients with enlarged prostates, mirroring how robotic-assisted prostatectomy became the dominant surgical approach for prostate cancer," said Harel Gadot, Chairman, CEO & President of Microbot Medical. "The successful completion of LIBERTY's cases at Emory reinforces our confidence in the innovation and benefits it can bring to clinicians, patients and procedural workflow."Microbot Medical commenced its Limited Market Release of LIBERTY in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026. The dual-indication proof-of-concept at Emory strengthens the commercial case ahead of that launch.LivaNova (NASDAQ: LIVN) received U.S. FDA premarket approval for its aura6000 System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea, making it the first and only hypoglossal nerve stimulation therapy approved in the U.S. without a complete concentric collapse contraindication or warning, and without requiring a pre-implantation drug-induced sleep endoscopy. The approval is backed by the OSPREY randomized controlled trial, which demonstrated a 65% responder rate at 12 months of proximal hypoglossal nerve stimulation therapy, with responders defined as achieving at least 50% AHI improvement and an AHI value below 20."FDA approval of the aura6000 marks a transformative moment for LivaNova and represents a major step forward for patients struggling with inadequately treated OSA," said Ahmet Tezel, Ph.D., Chief Innovation Officer for LivaNova. "Our p-HGNS therapy underwent a rigorous evaluation for safety and efficacy in the OSPREY randomized controlled trial and delivered clinically significant responses and sustained improvements over time. Now, with FDA approval secured, we are advancing the device toward an even more sophisticated, next-generation system for patients and, ultimately, commercialization."LivaNova is already preparing a PMA supplement application for a next-generation OSA device engineered for MRI compatibility, remote configuration management, and rechargeable battery technology projected to last up to 15 years, with a targeted launch in the first half of 2027. The aura6000 approval addresses a broad OSA patient population, having been validated in patients more severe than any other approved HGNS therapy.Clover Health Investments (NASDAQ: CLOV) released new evidence through its Counterpart Health subsidiary showing that primary care physicians using the Counterpart Assistant AI platform were associated with 22% fewer flu-related acute care encounters in COPD patients and 18% fewer in congestive heart failure patients. Patients whose physicians actively engaged with the platform's flu-related clinical insight were 1.89 times more likely to receive flu vaccination than those in the CA cohort whose providers did not engage with the task."The reductions in flu-related hospitalizations and emergency visits among high-risk patients reflect what we've seen within Clover Health's Medicare Advantage population," said Conrad Wai, CEO of Counterpart Health. "Equipping primary care with timely, actionable insights enables earlier intervention, fewer avoidable acute events, and lower total cost of care. It's not plan-specific. It's a scalable model enabling effective value-based care."The whitepaper, titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Flu Preventative Care," underscores Clover Health Investments' strategy of expanding the Counterpart Health platform beyond its own Medicare Advantage membership to serve a broader national provider base. The company continues developing AI-enabled clinical workflows targeting chronic disease management and value-based performance across Medicare populations.Further Reading: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/CONTACT:Equity Insiderinfo @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.ey.com/en_us/insights/strategy/healthcare-sector-outlook-in-2026https://blogs.nvidia.com/blog/ai-in-healthcare-survey-2026/https://www.beckersasc.com/asc-transactions-and-valuation-issues/the-biggest-asc-investments-so-far-in-2026/https://www.healthcare.digital/single-post/medtech-2026-trends-deals-and-investmentsLogo - https://mma.prnewswire.com/media/2840019/5886727/Equity_Insider_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtechs-edge-how-ai-and-remote-diagnostics-drive-scalable-value-302726894.html
Original: MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
subslover
9月前
Clover Health Launches New Portal Availity® Essentials™ to Empower Providers and Improve the Patient Experience
Clover Health Continues to Invest in Streamlining Provider Workflows and Reducing Administrative Burden Through Technology and Operational Improvements
WILMINGTON, Del., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, is leveraging Availity, the nation’s largest real-time health information network, for a multi-phase initiative designed to increase operational efficiency across administrative functions for providers while improving patient access to timely, quality care.
Across the healthcare system, providers face significant challenges managing prior authorizations, eligibility checks, and claims. These processes can take the focus away from patient care and create unnecessary administrative burden that can delay treatment and impact patient outcomes. As part of Clover's strategic commitment to operational excellence, the Company is investing in solutions that directly address these challenges while ensuring providers know their voices are heard and valued in shaping these improvements.
Key Enhancements
Centralized Access: A single, highly secure interface that allows providers to manage core administrative tasks across multiple health plans. This streamlined access means providers can spend more time with patients and less time navigating multiple systems.
Streamlined Prior Authorizations: Faster, more efficient approval workflows designed to reduce delays in patient care.
Real-Time Transparency: Tools for instant eligibility verification and advanced claims tracking, giving providers the information they need when they need it.
“Providers have been clear - they need less red tape and more support in focusing on patients,” said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. “This new portal is one of several steps we’re taking to ease administrative burden, accelerate decision-making, and deliver on our commitment to a more efficient provider experience, empowering them to focus on what they do best: delivering high quality care to their patients, faster.”
This collaboration is enabled by Availity’s position as the nation’s largest dual-sided network in healthcare, including 3.4 million providers, thousands of health IT vendors, and direct connectivity to more than 95 percent of health plans.
The new portal will be implemented in phases to ensure optimal performance and provider experience while minimizing any disruption to patient care. Clover is currently partnering with pilot providers to refine the system before expanding access across its full provider network.
“Clover Health’s rollout of our Availity Essentials demonstrates how health plans and providers can work together through Availity’s dual-sided network to reduce friction and deliver measurable value,” said Russ Thomas, CEO of Availity. “This collaboration reflects our vision for empowering stakeholders to make better decisions, experiences, interoperability, and scale in service of improving patient outcomes.”
This rollout builds on Clover Health's ongoing strategic initiatives to make working with the Company more efficient and less complex while improving the member experience, including:
Reducing the number of procedure codes requiring authorization, focusing only on areas with the highest potential for fraud, waste, or abuse.
Expanding electronic submissions underpinned by clinician reviews, with a majority of prior authorizations now processed digitally and more approved instantly. This enables providers to receive immediate feedback and proceed with patient care without delays, reducing administrative overhead.
Looking ahead, Clover is committed to working with providers and CMS to further accelerate prior authorization electronic submission adoption through standardized data and submission elements (using FHIR® APIs), expand real-time coverage determinations, and enhance determination transparency. This past month, Clover Health signed on as a CMS-Aligned Network early adopter, pledging to work collaboratively to enable the CMS Interoperability Framework goals and confirming Clover’s belief in a future where seamless care coordination and data-sharing for the patients’ needs are the norm, not the exception.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable,
subslover
9月前
Counterpart Health Launches Integrated Scribing, Supercharging Counterpart Assistant with Smarter, Seamless Scribing Built for Value-Based Care
The latest AI-powered feature in Counterpart Assistant streamlines documentation, enhances physician workflows, and raises the bar for value-based care across practice settings at no additional cost to users
SAN FRANCISCO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Counterpart Health,?Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq:?CLOV) (“Clover,” “Clover?Health” or the “Company”) and a leading AI-powered physician-enablement platform, today announced a major upgrade to Counterpart Assistant (CA): the launch of its fully integrated ambient scribing solution. With this release, CA just got smarter, turning every visit into a seamless, conversational experience that delivers better care with less effort. The capability will be available to all eligible physicians using CA, bringing enterprise-grade technology to every practice, including small independent offices where such tools are often out of reach.
Unlike standalone scribing tools, CA’s integrated solution is embedded directly into its value-based care platform, extending the same workflow that already empowers early diagnosis, care gap closure, and better clinical outcomes. Scribing alone is helpful in reducing documentation burden, but CA’s integrated solution goes further, strengthening CA’s ability to support clinicians in producing high-quality care outcomes.
CA’s scribing solution listens, learns, and works in real time. Powered by advanced AI, it generates a summary of available audio, surfaces insights in real time, and integrates seamlessly into the visit workflow. Physicians stay focused on patients, not administrative burden; patients benefit from more engaged visits and stronger relationships with their physicians. The desktop- and mobile-optimized experience supports multilingual conversations, letting clinicians use their phone, tablet, or computer microphone to capture visit dialogue and deliver patient-centered care in any setting.
“Our goal has always been to deliver clinical insights directly into the physician’s workflow, supporting better care and making every encounter more seamless,” said Conrad Wai, CEO of Counterpart Health. “By bringing scribing into value-based care, we are enabling clinicians to focus on managing care, rather than keeping up with documentation.”
Clover Health is providing this new capability at no cost to all clinicians using CA within its network, underscoring the company’s commitment to empowering physicians and elevating patient care.
“As an independent PCP, balancing patient care with extensive documentation demands is a daily challenge,” said Dr. Quinones, a Family Medicine doctor and early adopter of CA’s scribing solution. “The ambient scribe integrated into CA has tremendously saved me time, reduced my documentation burden, and diminished feelings of burnout. It allows me to focus more on what matters most — my patients."
The launch of CA scribing is part of a continuing wave of next-generation AI features that further enhance the physician experience and value-based care, setting a new standard for how clinicians and technology work together to deliver better care and continuing to prove that technology should work for physicians, not the other way around.
About Counterpart Health
Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies demonstrate the technology’s impact on Diabetes, Chronic Kidney Disease, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease management, and Clinical Quality.
Investor Relations:
Ryan Schmidt
investors@cloverhealth.com
Press Inquiries:
press@cloverhealth.com
subslover
10月前
See Spuds, the CEO knew that the bottom line was gonna suck rotten eggs, hence the millions of shares he and other insiders dumped.
Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth
Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year
Second quarter 2025 Total revenues of $478 million, up 34% year-over-year
Second quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million
Updates Full Year 2025 Guidance:
Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpoint
Maintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpoint
Improves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage of Total revenues between 18% - 19%
Maintains Adjusted EBITDA profitability between $50 million and $70 million
Maintains Adjusted Net income between $50 million and $70 million
Expects Insurance BER now between 88.5% - 89.5%
WILMINGTON, Del., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the second quarter 2025. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.
"Our performance further demonstrates how our technology-first model drives better care management, above-market growth, and sustained profitability," said Clover Health CEO Andrew Toy. “By leading with affordability, choice, and AI-driven clinical recommendations, we have achieved strong Medicare Advantage results this year to date, and importantly, better health outcomes for our members. Our recently published clinical whitepaper on chronic obstructive pulmonary disease (COPD) shows that a relationship with a provider using Clover Assistant technology was correlated with fewer hospitalizations (15% lower) and readmissions (18% lower).”
“Our second quarter 2025 results reflect significant membership and revenue growth, along with sustained Adjusted Net income and Adjusted EBITDA profitability,” said Clover Health CFO Peter Kuipers. “We are executing our growth strategy well, and have generated significant momentum in our business this year during a 3.5 Star payment year. We believe this positions us well to achieve our updated 2025 guidance and expect it to further accelerate our growth and profitability in 2026, which is a 4 Star payment year."
Key Company highlights are as follows:
Dollars in Millions 2Q25 2Q24 Change (%)
Insurance revenue $ 469.8 $ 349.9 34.3 %
Total revenues 477.6 356.3 34.0 %
Insurance net medical claims incurred 394.2 249.4 58.1 %
Salaries and benefits plus General and administrative expenses ("SG&A") 109.8 99.9 9.9 %
Adjusted Salaries and benefits plus General and administrative expenses ("Adjusted SG&A") (1) 82.5 71.7 15.1 %
Adjusted SG&A as a % of Total revenues 17.3 % 20.1 % (280 bps)
Net (loss) income from continuing operations $ (10.6 ) $ 7.2 N/A*
Adjusted Net income from continuing operations (1)(2) 16.7 35.9 (53.5 )%
Adjusted EBITDA (1) 17.1 36.2 (52.8 )%
Average Medicare Advantage membership (5) 105,494 80,016 31.8 %
Insurance BER (3) 88.4 % 76.1 % (1,230 bps)
Total cash, cash equivalents, and investments $ 389.3 $ 482.8 (19.4 )%
__________________________
*Not presented as a % change because the current or prior period amount is zero or the amount for the line item changed from a gain to a loss (or vice versa) and thus yields a result that is not meaningful.
1 Adjusted SG&A (Non-GAAP), Adjusted EBITDA (Non-GAAP), and Adjusted Net income from continuing operations (Non-GAAP) are Non-GAAP financial measures. Reconciliations of Adjusted SG&A (Non-GAAP) to SG&A, Adjusted EBITDA (Non-GAAP) to Net (loss) income from continuing operations, and Adjusted Net income from continuing operations (Non-GAAP) to Net loss from continuing operations, respectively, the most directly comparable GAAP measures, are provided in the tables immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A.
2 Adjusted Net income from continuing operations is a Non-GAAP financial measure. A reconciliation of Adjusted Net income from continuing operations to Net (loss) income from continuing operations, the most directly comparable GAAP measure, is provided in a table immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A. In the fourth quarter of 2024, the Company began presenting Adjusted Net income from continuing operations. Management believes that Adjusted Net income from continuing operations is helpful to investors in understanding and evaluating our operating performance and trends, as well as in assessing the Company’s financial performance in the same manner as our management and our board of directors.
3 Insurance Benefits Expense Ratio (“BER”) is a Non-GAAP financial measure. A reconciliation of Insurance BER to Insurance Net medical claims incurred, net, the most directly comparable GAAP measure, is provided in a table immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A. In the second quarter of 2024, the Company began presenting Insurance BER. Management believes that by adding quality improvement expenses into the Insurance BER calculation, it offers a clearer and more accurate representation of our investment in healthcare quality and member engagement, and more fully captures the cost of maintaining and enhancing the quality of care for our members.
4 Reconciliations of projected Adjusted SG&A (Non-GAAP) to projected SG&A, projected Adjusted EBITDA (Non-GAAP) to Net income, and projected Adjusted Net income (Non-GAAP) to Net income, the most directly comparable GAAP measures, are not provided because Stock-based compensation, which is excluded from Adjusted SG&A (Non-GAAP), Adjusted EBITDA (Non-GAAP), and Adjusted Net income (Non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. A reconciliation of projected Insurance BER (Non-GAAP) to projected Net medical claims incurred, net, the most directly comparable GAAP measure, is not provided because quality improvements, which are included in Insurance BER (Non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. Additional information about the Company's Non-GAAP financial measures can be found under the caption “About Non-GAAP Financial Measures” below and in Appendix A.
5 Average Medicare Advantage membership represents the average membership during the three months included in the second quarter of 2025.
Financial Guidance
For full-year 2025, Clover Health is updating its guidance as follows:
Current 2025 Guidance Previous 2025 Guidance
Insurance revenue $1.800 billion - $1.875 billion $1.800 billion - $1.875 billion
Adjusted SG&A (4) $335 million - $345 million $355 million - $365 million
Adjusted SG&A as a % of Total revenues 18% - 19% 19% - 20%
Adjusted EBITDA (4) $50 million - $70 million $50 million - $70 million
Adjusted Net income (2)(4) $50 million - $70 million $50 million - $70 million
Average Medicare Advantage membership 104,000 - 108,000 103,000 - 107,000
Insurance BER (4) 88.5% - 89.5% 87% - 88%
Lives under Clover Management
June 30, 2025 June 30, 2024
Insurance members 106,323 80,261
Earnings Conference Call Details
Clover Health’s management will host a conference call to discuss its financial results on Tuesday, August 5, 2025, at 5:00 PM Eastern Time. To access the call via telephone, please dial 800-245-3047 (for U.S. callers) or 203-518-9765 (for callers outside the U.S.) and enter the conference ID: CLOVQ225. A live audio webcast will also be available online at: https://event.on24.com/wcc/r/5004864/5729A47D06B46D779C215395F221D12A and related presentation materials will be available at Clover Health’s Investor Relations website at investors.cloverhealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link and at Clover Health’s Investor Relations website at investors.cloverhealth.com, and will remain available for approximately 12 months.
Upcoming Investor Events & Conferences
2025 Canaccord Genuity 45th Annual Growth Conference at 11:00 a.m. Eastern Time, Tuesday, August 12, 2025
Any live and archived webcasts and presentations associated with the conferences listed above may be accessed on Clover Health’s Investor Relations website at: investors.cloverhealth.com/news-and-events/investor-events-presentations.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and Clover Health's future results of operations, financial condition, market size and opportunity, business strategy and plans, and the factors affecting our performance and our objectives for future operations. Forward-looking statements are not guarantees of future performance and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "can," "could," "should," "would," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "outlook," "forecast," "guidance," "objective," "plan," "seek," "grow," "if," "continue" or the negative of these words or other similar terms or expressions that concern Clover Health's expectations, strategy, priorities, plans or intentions. Forward-looking statements in this press release include, but are not limited to, the following: statements under "Financial Guidance" and statements regarding expectations relating to potential improvements in revenues, operating expenses, Adjusted SG&A, Insurance BER, and the number of Clover Health's Insurance members, as well as the statements contained in the quotations of our executive officers, and other expectations as to future performance, operations and results (including our guidance for full year 2025). Statements regarding our Adjusted EBITDA profitability and Adjusted Net income profitability are also forward-looking, and are based on our current targets which are preliminary and are derived from our 2025 financial guidance. These statements are subjec
subslover
11月前
Clover Health Launches New Jersey Community Pharmacy Program in Partnership with IPC’s iCare+ Network
WILMINGTON, Del., July 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a leading Medicare Advantage company committed to affordable, high-quality care, today announced the launch of a new community-based pharmacy pilot program across New Jersey. Built in partnership with IPC Digital Health™, a division of Independent Pharmacy Cooperative (IPC), this initiative is designed to help seniors better manage their medications and stay healthier at home, supported by the local pharmacies they know and trust.
The program will be anchored by IPC’s iCare+™ Independent Pharmacy Network, which includes thousands of community-rooted pharmacies nationwide and many in New Jersey. These local pharmacies will deploy innovative care tools and virtual services that help Clover members with chronic conditions stay on track with their medications and avoid unnecessary hospital visits.
“This is more than a new program—it’s a new model for how we support our New Jersey members,” said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. “By working with the pharmacists who are already embedded in our communities, we can deliver better care, deliver amazing customer experiences and support the independent businesses that keep New Jersey strong.”
Participating iCare+ pharmacies will use real-time tools, powered by Clover Assistant data and AI models, to monitor prescription fills, identify adherence gaps, and collaborate with local doctors and Clover’s care teams. The goal: make it easier for seniors to get the right medications at the right time, while keeping their care close to home.
“Clover Health understands that innovation doesn’t always mean centralization,” said Ashton Maaraba, President of IPC Digital Health. “This partnership helps New Jersey’s independent pharmacies lead the way in delivering smarter, more connected care.”
This new program is part of Clover’s broader commitment to investing in New Jersey communities, by combining modern technology, local relationships, and a belief that healthcare should feel personal again.
subslover
1年前
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year
First quarter 2025 Total revenues of $462 million, up 33% year-over-year
Medicare Advantage medical costs are in line with expectations, underscoring the strength of Clover’s technology-first care management model
Meaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year
Improved Full Year 2025 Guidance:
Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpoint
Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpoint
Adjusted EBITDA profitability between $50 million and $70 million
Adjusted Net income between $50 million and $70 million
WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the first quarter 2025. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.
"I am very pleased with our strong start to the year, demonstrating our ability to meaningfully grow membership and expand profitability," said Clover Health CEO Andrew Toy. "Our differentiated model is designed to drive scalable growth and proactively manage our medical costs amidst regulatory changes, outperforming others in the industry, with Clover Assistant. Our recently published clinical whitepaper on Congestive Heart Failure shows that a relationship with a Clover Assistant provider was associated with lower average number of all-cause hospitalizations (18% lower) and 30-day readmissions (25% lower)."
"Our strong first quarter 2025 financial results reflect the execution of our strategic plan to grow revenue and membership above-market rates, while continuing to drive profitability. First quarter 2025 medical costs are in line with expectations," said Clover Health CFO Peter Kuipers. "Our results and strong underlying business fundamentals further reinforce our conviction in 2025, and we will continue to strategically invest into our growth model, manage our new and returning member cohorts, and expand Clover Assistant’s reach, to enhance our already strong competitive positioning in 2026 and beyond."
Key Company highlights are as follows:
Dollars in Millions 1Q25 1Q24 Change (%)
Insurance revenue $ 456.9 $ 341.7 33.7 %
Total revenues 462.3 346.9 33.3 %
Insurance net medical claims incurred 367.9 266.1 38.3 %
Salaries and benefits plus General and administrative expenses ("SG&A") 109.7 103.8 5.7 %
Adjusted Salaries and benefits plus General and administrative expenses ("Adjusted SG&A")(1) 83.1 74.9 10.9 %
Adjusted SG&A as a % of Total revenues 18.0 % 21.6 % (360 bps )
Net loss from continuing operations $ (1.3 ) $ (23.2 ) 94.4 %
Adjusted Net income from continuing operations(1)(2) 25.3 6.0 321.7 %
Adjusted EBITDA(1) 25.8 6.8 279.4 %
Average medicare advantage membership(5) 101,959 79,265 28.6 %
Insurance BER(3) 86.1 % 83.2 % 290 bps
Total cash, cash equivalents, and investments $ 390.8 $ 440.3 (11.2)%
Financial Outlook
For full-year 2025, Clover Health is improving its guidance as follows:
Current 2025 Guidance Previous 2025 Guidance
Insurance revenue $1.800 billion - $1.875 billion $1.800 billion - $1.875 billion
Adjusted SG&A(4) $355 million - $365 million $355 million - $365 million
Adjusted SG&A as a % of Total revenues 19% - 20% 19% - 20%
Adjusted EBITDA(4) $50 million - $70 million $45 million - $70 million
Adjusted Net income(2)(4) $50 million - $70 million $45 million - $70 million
Average Medicare Advantage membership 103,000 - 107,000 103,000 - 107,000
Insurance BER(4) 87% - 88% 87% - 88%
Lives under Clover Management
March 31, 2025 March 31, 2024
Insurance members 103,418 79,527
Earnings Conference Call Details
Clover Health’s management will host a conference call to discuss its financial results on Tuesday, May 6, at 5:00 PM Eastern Time. To access the call via telephone, please dial 800-274-8461 (for U.S. callers) or 203-518-9814 (for callers outside the U.S.) and enter the conference ID: CLOVQ125. A live audio webcast will also be available online at: https://event.on24.com/wcc/r/4907810/54258C9AF223D84ADCF625A1618CDA44 and related presentation materials will be available at Clover Health’s Investor Relations website at investors.cloverhealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link and at Clover Health’s Investor Relations website at investors.cloverhealth.com, and will remain available for approximately 12 months.
Upcoming Investor Events & Conferences
2025 Bank of America Healthcare Conference at 6:00 p.m. Eastern Time, Wednesday, May 14, 2025
22nd Annual Craig-Hallum Institutional Investor Conference, Wednesday, May 28, 2025
Any live and archived webcasts and presentations associated with the conferences listed above may be accessed on Clover Health’s Investor Relations website at: investors.cloverhealth.com/news-and-events/investor-events-presentations.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and Clover Health's future results of operations, financial condition, market size and opportunity, business strategy and plans, and the factors affecting our performance and our objectives for future operations. Forward-looking statements are not guarantees of future performance and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "can," "could," "should," "would," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "outlook," "forecast," "guidance," "objective," "plan," "seek," "grow," "if," "continue" or the negative of these words or other similar terms or expressions that concern Clover Health's expectations, strategy, priorities, plans or intentions. Forward-looking statements in this press release include, but are not limited to, the following: statements under "Financial Guidance" and statements regarding expectations relating to potential improvements in operating expenses, Adjusted SG&A, Insurance BER, and the number of Clover Health's Insurance members, as well as the statements contained in the quotations of our executive officers, future capital needs and other expectations as to future performance, operations and results (including our updated guidance for full-year 2025). Statements regarding our Adjusted EBITDA profitability and Adjusted Net income profitability are also forward-looking, and are based on our current targets which are preliminary and are derived from our 2025 financial outlook. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or im
subslover
1年前
Counterpart Health Partners with Google Cloud to Improve Clinical Data Access for Physicians
New functionality within Counterpart Assistant uses Google Cloud’s Vertex AI Search to give clinicians comprehensive insights across multiple sources of patient health data
WILMINGTON, Del., March 03, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform, today announced it has partnered with Google Cloud to integrate Vertex AI Search into its flagship technology, Counterpart Assistant. This innovation gives providers on Counterpart Assistant a generative AI (gen AI) search experience across the breadth of a patient’s digital health record to provide contextualized insights, and to make it easier to deliver value-based care. Counterpart is a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”).
Physicians struggle to access and synthesize the vast amounts of data within patient health records. Fragmented EHR systems hinder a unified patient history view, slowing clinical decisions and consuming valuable time. The increasing volume of medical information further complicates effective patient care.
Unlike traditional siloed systems, Counterpart Assistant synthesizes data from more than 100 sources from across the healthcare landscape such as recent tests, hospital discharges, and medication adherence, to provide a single, comprehensive view of a patient’s history. With the integration of Vertex AI Search, physicians now benefit from Google Cloud’s leading large language models (LLMs) and AI platform, Vertex AI, all within the intuitive Counterpart Assistant platform.
Key features of Counterpart Assistant’s search functionality include:
Unified Search: Access all patient documents in one place, across multiple data sources.
AI-Generated Insights: Receive intelligent natural language answers to search queries powered by Google Cloud’s Vertex AI Search.
Clinical Evidence Citations and Verification: Expand citations to view supporting data for AI-generated responses.
Contextual Data Highlighting: Instantly locate specific phrases and keywords with highlighted snippets.
“Physicians are often under-resourced and lack access to cutting-edge technologies that can simplify care delivery,” said David Tsay, MD, chief medical officer at Counterpart. “Our goal with Counterpart Assistant is to bring all the leading edge tools under one roof, layer them over a single source of normalized data, and give clinicians what they need to make informed decisions—without the burden of fragmented solutions.”
This partnership with Google Cloud further solidifies Counterpart’s reputation as a leader in building technology-first, cloud-native solutions for physicians. Counterpart’s ability to seamlessly integrate best-in-breed technologies like Vertex AI Search within its proprietary platform demonstrates its commitment to equipping clinicians with the tools they need to provide exceptional care.
“Clinicians are spending nearly 28 hours a week on administrative tasks, and 82% are reporting burnout,” said Aashima Gupta, global director of Healthcare Strategy & Solutions, Google Cloud. “Gen AI-powered search can help alleviate some of this burden, and Counterpart Health's integration of Vertex AI Search will empower physicians to access critical patient information quickly and efficiently, helping them refocus on what matters most: better patient care."
Conrad Wai, CEO of Counterpart added, “At Counterpart, we believe practicing clinicians deserve technologies that help them focus on delivering exceptional patient care. This enhancement demonstrates Counterpart Assistant’s commitment to simplifying value-based care by presenting clinical insights in the context of care delivery, so patient outcomes naturally align with performance targets. With earlier diagnoses, better chronic disease management, and streamlined workflows, clinicians can focus on caring for their patients, while excelling in value-based care programs.”
To learn more about Counterpart Health, visit: www.counterparthealth.com.
About Counterpart Health
Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI powered physician enablement platform. Counterpart Health’s flagship software platform, Counterpart Assistant, was incubated by Clover Health as Clover Assistant and has helped improve plan performance and clinical outcomes for Medicare members through proprietary AI technology. Counterpart Health extends the benefits of the data-driven technology platform outside of Clover Health’s Medicare Advantage plan to a wider audience, to enable enhanced patient outcomes and reduced healthcare costs nationwide. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Spuds McKenz66
16時間前
makinezmoney
4週前
Jimmy Joe
5月前
TommyBoyTrader9460
8月前
MadeMillions$
1年前
JayB2022
1年前
Monksdream
1年前
メールアドレスで登録
